Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
high-fat (HF) diet | increase | body mass gain | C57BL/6 mice | +28% | induced | #1 |
high-fat (HF) diet | increase | hepatic triacylglycerol levels | C57BL/6 mice | +40% | induced | #2 |
high-fat (HF) diet | increase | hepatic angiotensinogen (AGT) expression | C57BL/6 mice | +50% | induced | #3 |
high-fat (HF) diet | increase | hepatic angiotensin-converting enzyme 1 (ACE1) expression | C57BL/6 mice | +50% | induced | #4 |
high-fat (HF) diet | increase | hepatic angiotensin II type 1 receptor (AT1r) expression | C57BL/6 mice | +50% | induced | #5 |
losartan or telmisartan treatments | decrease | hepatic triacylglycerol levels | C57BL/6 mice | - | reduced | #6 |
losartan or telmisartan treatments | decrease | PLIN 2 expression | C57BL/6 mice | - | reduced | #7 |
losartan or telmisartan treatments | increase | glycemic control | C57BL/6 mice | - | improved | #8 |
losartan or telmisartan treatments | increase | hepatic and metabolic beneficial effects | C57BL/6 mice | - | caused | #9 |
BACKGROUND: Obesity has been associated with hepatic overexpression of the renin-angiotensin system (RAS). AIM: To evaluate the action of two angiotensin II (ANGII) receptor blockers (losartan or telmisartan) on the modulation of local hepatic RAS and the resulting metabolic effects in a diet-induced obesity murine model. METHODS: Twenty C57BL/6 mice were randomly divided into two nutritional groups for 10 wk: control group (C, RESULTS: HF diet induced body mass gain (+28%, CONCLUSION: Modulation of the intrahepatic RAS, with favored involvement of the ACE2/rMAS axis over the ACE1/AT1r axis after losartan or telmisartan treatments, caused hepatic and metabolic beneficial effects as demonstrated by reduced hepatic triacylglycerol levels coupled with reduced PLIN 2 expression and improved glycemic control.